Skip to content
value.today

Complete Genomics Inc.

Total raised
$14 M
1 round on record
Latest round
$14 M
Feb 2009
First round on record
Feb 2009
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Complete Genomics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2009$14 MNo. 1$10 to $50 million

Complete Genomics Inc.: Raise no. 1, Feb 2009

Investors in this round

9 investors had bought by the notice of Jul 2, 2009: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Complete Genomics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Clifford A. Reid · Executive Officer, Director
  • Robert J. Curson · Executive Officer
  • Alexander E. Barkas, Ph.D. · Director
  • Andrew Senyei, M.D. · Director
  • Charles P. Waite, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 2, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Complete Genomics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2009).

    SEC Form D · Jul 2009

  • It delivers 1 product named in the sources below.

    See Products and services

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2009

Products#

1 named by the sources below.

  • Complete Genomics Data File Format

    Wikidata · Wikidata: product or material produced (P1056)

Services#

No services of Complete Genomics Inc. are on record.

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Complete Genomics Inc.
InvestorKindAmountRoundRoleSource
C. Thomas CaskeyPersonnot statednot statedHeld Series D and E preferred stock, director (Form 3, 2010)SEC Form 3
Enterprise Partners Management LLCFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Enterprise Partners VI LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Enterprise Partners V L.P.Fund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Essex Woodlands Health Ventures Fund VIII-A LPVenture capitalnot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Essex Woodlands Health Ventures Fund VIII-B LPVenture capitalnot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Essex Woodlands Health Ventures Fund VIII LPVenture capitalnot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Highland Capital Management LPFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
OrbiMed Capital GP III LLCFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Ovp Venture Partners VI LPVenture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Prospect Management Co. III, L.L.C.Fund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Prospect Venture Partners III L.P.Venture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3
Strand Advisors, Inc.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2010)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Complete Genomics Inc.
NameRoleNamed in
Clifford A. ReidExecutive officerJul 2009
Robert J. CursonExecutive officerJul 2009
Alexander E. Barkas, Ph.D.DirectorJul 2009
Andrew Senyei, M.D.DirectorJul 2009
Charles P. Waite, Jr.DirectorJul 2009
Clifford A. ReidDirectorJul 2009

About

Life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis.